Cargando…
Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database
PURPOSE: Infliximab, which was approved in 2002, had its first biosimilar launched in 2014 across Japan. However, the penetration rate of this biosimilar remains unclear given the limited data regarding its current clinical use throughout Japan. This study was conducted to describe the current clini...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920501/ https://www.ncbi.nlm.nih.gov/pubmed/33658813 http://dx.doi.org/10.2147/CEOR.S293698 |